Apoptosis or necrosis for tumor immunotherapy: What's in a name?

Journal of Molecular Medicine

Volumn 77, Issue 12, 1999, Pages 824-833

  Melcher, Alan ^a   Gough, Michael ^a   Todryk, Stephen ^b   Vile, Richard ^a  

^a MAYO CLINIC   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; Gene therapy; Immunotherapy; Necrosis

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CELL DEATH; DENDRITIC CELL; GENE TRANSFER; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; TUMOR NECROSIS;

EID: 0033380292     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001099900066     Document Type: Review

References (57)

1. 1. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
2. 2. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
3. 3. Bell DA, Morrison B (1991) The spontaneous apoptotic death of normal human lymphocytes in vitro: the release of and immunoproliferative response to nucleosomes in vitro. Clin Immunol Immunopathol 60:13-26
4. 4. Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA (1997) Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 159:5391-5399
5. 5. Bird DA, Gillotte KL, Horkko S, Friedman P, Dennis EA, Witztum JL, Steinberg D (1999) Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc Natl Acad Sci USA 96: 6347-6352
6. 6. Breloer M, Fleischer B, von Bonin A (1999) In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol 162:3141-3147
7. 7. Casciola-Rosen LA, Anhalt GJ, Rosen A (1995) DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 182:1625-1634
8. 8. Cavallo F, Di Pierro F, Giovarrelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G (1993) Protective and curative potential of vaccination with interleukin-2-gene transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 53:5067-5070
9. 9. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T (1997) Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 158: 2834-2841
10. 10. Chang M-K, Bergmark C, Laurila A, Horkko S, Han K-H, Friedman P, Dennis EA, Witztum JL (1999) Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 96:6353-6358
11. 11. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP (1999) Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 190:125-134
12. 12. Chong H, Hutchinson G, Hart IR, Vile RG (1996) Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic anti-tumor immunity. Hum Gene Ther 7:1771-1779
13. 13. Colombo MP, Forni G (1996) Immunotherapy: cytokine gene transfer strategies. Cancer Metastasis Rev 15:317-328
14. 14. Colombo MP, Modesti A, Parmiani G, Forni G (1992) Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52:4853-4857
15. 15. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
16. 16. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit pro-inflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 101:890-898
17. 17. Freeman SM, Ramesh R, Marrogi AJ (1997) Immune system in suicide gene therapy. Lancet 349:2-3
18. 18. Fuchs EJ, Matzinger P (1996) Is cancer dangerous to the immune system? Semin Immunol 8:271-280
19. 19. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5: 7-16
20. 20. Hellstrom KE, Hellstrom I, Chen L (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145:123-145
21. 21. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90:2774-2778
22. 22. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamanstein T, Blankenstein T (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53:714-716
23. 23. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4
24. 24. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
25. 25. Kurts C, Miller JFAP, Subramaniam RM, Carbone FR, Heath WR (1998) Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188: 409-414
26. 26. Lukacs KV, Nakakes A, Atkins CJ, Lowrie DB, Colston MJ (1997) In vivo gene therapy of malignant tumors with heat shock protein-65 gene. Gene Ther 4:346-350
27. 27. Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. Am J Pathol 146:3-15
28. 28. Matzinger P (1994) Tolerance, danger and the extended family. Annu Rev Immunol 12:991-1045
29. 29. Matzinger P (1998) An innate sense of danger. Semin Immunol 10:399-415
30. 30. Melcher AA, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG (1998) Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4:581-587
31. 31. Moolten FL (1994) Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1:279-287
32. 32. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311
33. 33. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415
34. 34. Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96:5340-5342
35. 35. Parmiani G (1993) Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 14:536-538
36. 36. Peng K-W, Vile R (1999) Vector development for cancer gene therapy. Tumor Targeting (in press)
37. 37. Rajasekar R, Sim GK, Augustin A (1990) Self heat shock and gamma delta T-cell reactivity. Proc Natl Acad Sci USA 87:1767-1771
38. 38. Ren Y, Savill J (1998) Apoptosis: the importance of being eaten. Cell Death Differ 5:563-568
39. 39. Ridge JP, Fuchs EJ, Matzinger P (1996) Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271:1723-1726
40. 40. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Pia Protti M, Paola Garancini M, Manfredi AA, Rugarli C, Bellone M (1999) Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 163:130-136
41. 3 integrin and requires intracellular and extracellular calcium. Eur J Immunol 27:1893-1900
42. 42. Savill J (1998) Phagocytic docking without shocking. Nature 392:442-443
43. 43. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL (1998) Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8:657-665
44. 44. Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585-1588
45. 45. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120
46. 46. Tanaka K, Gorelik E, Watanabe M, Hozumi N, Jay G (1988) Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol 8:1857-1861
47. 47. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG (1999) Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163:1398-1408
48. 48. Townsend SE, Allison JP (1993) Tumor rejection after direct co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370
49. 49. Udono H, Levey DL, Srivastava PK (1994) Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 91:3077-3081
50. 50. Verma I, Somia N (1997) Gene therapy - promises, problems and prospects. Nature 389:239-242
51. 51. Vile RG, Chong H (1996) Immunotherapy: combinatorial molecular immunotherapy - a synthesis and suggestions. Cancer Metastasis Rev 15:351-364
52. 52. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228-6234
53. 53. Vile RG, Castleden SC, Marshall J, Camplejohn R, Upton C, Chong H (1997) Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 71:267-274
54. 54. Vile RG, Sunassee K, Diaz RM (1998) Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today 4:84-92
55. 55. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 380:350-351
56. 56. Wei Y-Q, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A (1996) Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of yd T cells and heat shock protein 70. Cancer Res 56:1104-1110
57. 57. Wyllie AH (1993) Apoptosis: the 1992 Frank Rose Memorial Lecture. Br J Cancer 67:205-208